Characteristics of Patients with Liver Cirrhosis Attending Azadi Center of Gastroenterology and Hepatology-Duhok Kurdistan Region
DOI:
https://doi.org/10.56056/401Keywords:
Cirrhosis, Causes, Complications, Duhok, PrognosesAbstract
Background and objectives: Diagnosis of liver cirrhosis is made histologically, yet patients can present with clinical and laboratory features suggestive of end-stage liver disease and cirrhosis. The aim was to identify the causes, severity, and complications.
Methods: A cross-sectional study was conducted from March-October 2023 in the Azadi Center of Gastroenterology and Hepatology in Duhok and included 205 cases. Demographic information was taken from the patients. Then patients were examined and sent to baseline and relevant investigations. A liver biopsy was done in selected patients.
Results: The mean age of the patients was 52.4 ± 13.1. years. Males were (57.6%), and non-smokers were (68.3%). Furthermore, (64.4%) of the patients had Anorexia, (52.7%) had weight loss, (46.8%) had fever, and (43.4%) had abdominal pain. Upper endoscopic findings revealed varices in (48.8%), Portal Hypertensive Gastropathy (13.17%), Gastric Antral Vascular Ectasia (8.8%) and erosive gastritis in (3.41%). The metabolic dysfunction associated steatotic liver disease (31.22%), hepatitis B (15.61%), cryptogenic (11.22%), and hepatitis C (5.37%) were the most common types. Regarding the severity, chronic liver disease stage B was the most prevalent type (57.56%) and then type A was (21.46%). The mean scores of the Child-Pugh and the model of end stage liver disease-Sodium score were 8.05 and 18.19, respectively, which are statistically significant.
Conclusion: Ascites and esophageal varices as a complication on presentation implies a delay in the presentation and diagnosis alongside under screening for liver cirrhosis. Metabolic dysfunction associated steatotic liver disease plays a major role as an underlying cause.
Downloads
References
1. Mark Feldman, MD, Lawrence S. Friedman, MD, and Lawrence J. Brandt, MD. Sleisenger and Fordtran's gastrointestinal and liver disease-overview liver cirrhosis, Eleventh edition, Elsevier/Saunders, Philadelphia, PA, 2021, PP 1164-1171.
2. Scaglione S, Kliethermes S, Cao G, The Epidemiology of Cirrhosis in the United States: A Population-based Study. J Clin Gastroenterol. 2015;49 (8):690-696. doi:10.1097/MCG.0000000000000208/
3. Delgado-Ramallo JF, Ceballos-Cuevas L, Álvarez-Gil M. Phaeodactylum tricornutum as Fucoxanthin Biofactory Model and Hepatoprotective Effect of Encapsulated Spirulina and Fucoxanthin. Appl Sci. 2023; 13(13):7794. https://doi.org/10.3390/app13137794/
4. Schuppan D, Afdhal NH. Liver cirrhosis. The Lancet. 2008;371(9615):838-51.
5. Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013;110(6):85-91. doi:10.3238/arztebl.2013.0085/
6. Brown C, Aksan N, Muir AJ. MELD-Na Accurately Predicts 6-Month Mortality in Patients with Decompensated Cirrhosis: Potential Trigger for Hospice Referral. J Clin Gastroenterol. 2022;56(10):902-907. doi:10.1097/MCG.0000000000001642/
7. Peng Y, Qi X, Guo X. Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95 (8): e2877. doi:10.1097/MD.0000000000002877/
8. Botta F, Giannini E, Romagnoli P, MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003;52(1):134-139. doi:10.1136/gut.52.1.134/
9. Al Kaabi H, Al Alawi AM, Al Falahi Z, Al-Naamani Z, Al Busafi SA. Clinical Characteristics, Etiology, and Prognostic Scores in Patients with Acute Decompensated Liver Cirrhosis. J Clin Med. 2023;12(17):5756. Published 2023 Sep 4. doi:10.3390/jcm12175756/
10. Siddiqua A, Rishad MM, Noor N, Reza IB, Das A, Ahasan HAMN, et al. Endoscopic Features of Chronic Liver Disease Patients Admitted in a Tertiary Care Hospital in Bangladesh- A Cross-Sectional Study. J. Med. 2023 Jul; 24 (2):135-8. https://www.banglajol.info/index.php/JOM/article/view/67277/
11. Kim Y, Kim K, Jang I. Analysis of mortality prognostic factors using model for end-stage liver disease with incorporation of serum-sodium classification for liver cirrhosis complications: A retrospective cohort study. Medicine (Baltimore). 2019;98 (45): e17862. doi:10.1097/MD.0000000000017862/
12. Li B, Zhang C, Zhan YT. Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Its Epidemiology, Risk Factors, Clinical Presentation, Diagnosis, Management, and Prognosis. Can J Gastrenterol Hepatol.2018 Jul.2:2018:2784537. Doi: 10.1155/2018/2784537.eCollection 2018.
13. Ismael SA, Ahmed HF, Hasan MF. Prevalence of Metabolic Syndrome in a Sample of Population in Erbil City, Iraq. Zanc J Med Sci 2016, 20, 1280-1287.
14. Svoboda P, Konecny M, Martinek A, Hrabovsky V, Prochazka V, Ehrmann J. Acute upper gastrointestinal bleeding in liver cirrhosis patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012; 156 (3):266-70.
15. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014;5(3):211-218. doi:10.1136/flgastro-2013-100403/
16. Hadayat R;Jehangiri AU;Gul R;Khan AN;Said K;Gandapur A. Endoscopic findings of upper gastrointestinal bleeding in patients with liver cirrosis. J Ayub Med Coll Abbottabad. 2015 Apr-Jun;27(2):391-4. JAMC. https://pubmed.ncbi.nlm.nih.gov/26411125/
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Mustafa Qasim Abdullah, Ali Abdulghani Ramathan, Azad Salih Muhammed
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
